What is Celcuity's accrued clinical trial costs?

Celcuity (CELC) reported accrued clinical trial costs of $8.77M in Q1 2026.

What does accrued clinical trial costs mean?

This represents the estimated financial obligations incurred for clinical research activities that have been performed but not yet invoiced or paid by the company. It reflects the near-term cash outflow requirements necessary to sustain ongoing drug development programs and clinical trials.

Celcuity CELC Accrued Clinical Trial Costs

Accrued Clinical Trial Costs at other companies

ExelixisEXEL

$64.8M+12.4%

BillionToOne, Inc. BLLN

$224K—

Ionis PharmaceuticalsIONS

$53.33M-21.1%

Spyre Therapeutics, Inc.SYRE

$29.16M+34.8%

Nuvalent, Inc.NUVL

$58.92M+20.6%

Praxis Precision Medicines, Inc.PRAX

$17.65M+13.5%

Other financials

Income statement

See full

Operating income-$50.5M-39.8%

Net income-$52.8M-42.8%

EPS (diluted)-$0.97-12.8%

Balance sheet

See full

Cash & equivalents$145.2M+781%

Total debt$137.9M+30.7%

Total equity$53.5M-38.2%

Total assets$410.2M+88.0%

Cash flow

See full

Operating cash flow-$55.1M-53.6%

CapEx$249.0K+315%

Free cash flow-$55.3M-54.0%

Valuation

See full

Market cap$4.4B+1,370%

Returns & leverage

See full

Return on equity-275.2%-990pp

Debt / equity2.6×+1.4×

Current ratio12.3×+5.7×

Where this comes from

Reported directly by Celcuity in its filing.

Tagged under the XBRL concept CELC:AccruedClinicalTrialCosts.

The official record: Celcuity’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Celcuity's accrued clinical trial costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Celcuity's accrued clinical trial costs?: Celcuity (CELC) reported accrued clinical trial costs of $8.77M in Q1 2026.
What does accrued clinical trial costs mean?: This represents the estimated financial obligations incurred for clinical research activities that have been performed but not yet invoiced or paid by the company. It reflects the near-term cash outflow requirements necessary to sustain ongoing drug development programs and clinical trials.